Related Experiment Videos
Subclinical thyrotoxicosis and the heart
Lynn A Burmeister1, Angel Flores
1Division of Endocrinology & Metabolism, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. LynnBMD@aol.com
Summary
Subclinical thyrotoxicosis, characterized by low TSH with normal thyroid hormones, can affect cardiac function. Treatment is recommended for patients with cardiac symptoms or disease.
Area of Science:
- Endocrinology
- Cardiology
Background:
- Subclinical thyrotoxicosis involves suppressed thyrotropin (TSH) with normal thyroid hormones (T4, T3).
- It can result from thyroid hormone therapy or endogenous thyroid conditions.
- TSH suppression level indicates the severity of thyrotoxicosis.
Purpose of the Study:
- To review the cardiac implications of subclinical thyrotoxicosis.
- To discuss the current understanding of its association with cardiac performance and morphology.
- To outline treatment strategies for affected patients.
Main Methods:
- Literature review of studies investigating subclinical thyrotoxicosis and cardiac effects.
- Analysis of findings on cardiac performance, morphology, and arrhythmias.
- Synthesis of treatment recommendations based on existing evidence.
Main Results:
- Inconsistent findings regarding cardiac changes across patient populations.
- Potential cardiac alterations include increased heart rate, left ventricular mass, and contractility.
- Diastolic dysfunction, ectopic atrial beats, and impaired exercise performance may occur.
Conclusions:
- Subclinical thyrotoxicosis may impact cardiac function and morphology.
- Treatment is indicated for patients experiencing cardiac symptoms or with existing cardiac disease.
- Management options include adjusting thyroid hormone dosage, treating the underlying thyroid disorder, or using beta-blockers.